levofloxacin
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pneumonia
Conditions
Pneumonia
Trial Timeline
Mar 1, 2001 → Jun 1, 2002
NCT ID
NCT00236821About levofloxacin
levofloxacin is a phase 3 stage product being developed by Johnson & Johnson for Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT00236821. Target conditions include Pneumonia.
What happened to similar drugs?
4 of 20 similar drugs in Pneumonia were approved
Approved (4) Terminated (3) Active (14)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (18)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00002249 | Phase 1 | Completed |
| NCT00210886 | Phase 3 | Completed |
| NCT00645437 | Phase 1 | Completed |
| NCT00236652 | Phase 3 | Completed |
| NCT00044473 | Phase 3 | Completed |
| NCT00236522 | Phase 3 | Completed |
| NCT00034736 | Phase 3 | Completed |
| NCT00236821 | Phase 3 | Completed |
| NCT00236808 | Phase 3 | Completed |
| NCT00249197 | Phase 3 | Completed |
| NCT00269932 | Phase 3 | Completed |
| NCT00249210 | Phase 3 | Completed |
| NCT00258089 | Phase 3 | Completed |
| NCT00258102 | Phase 3 | Completed |
| NCT00257062 | Phase 3 | Completed |
| NCT00257036 | Phase 2/3 | Completed |
| NCT00257049 | Phase 2/3 | Completed |
| NCT00257140 | Phase 2/3 | Completed |
Competing Products
20 competing products in Pneumonia